Affiliation:
1. Department of Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, Delhi, India
2. Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, Delhi, India
Abstract
ABSTRACT
Anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is a molecularly distinct subgroup of oncogene-addicted NSCLC, accounting for 3-5% of cases. These are mainly genomic rearrangements resulting in a fusion oncoprotein, thus causing persistent constitutive signaling. Recent developments and approvals of various generations of ALK inhibitors have revamped the therapeutic and prognostic landscape of this disease entity. For the preparation of this review, we searched various databases such as PubMed, Embase, and Scopus, using the keywords “ALK,” “ALK crizotinib,” “Oncogene NSCLC,” and “Alectinib,” and we finally included 46 articles. In this review, we describe the molecular biology and pathologic and clinical characteristics of ALK-rearranged NSCLC. The detection methods, therapeutic strategies, and trials will be discussed in the next part of this biomarker review series.
Subject
Cancer Research,Oncology (nursing),Drug Guides,Oncology
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Uniqueness of lung cancer in Southeast Asia;The Lancet Regional Health - Southeast Asia;2024-08
2. Molecular analysis for EGFR, ALK, and ROS1 alterations in over 3000 Indian patients with non-small-cell lung cancer: A retrospective observational study;Cancer Research, Statistics, and Treatment;2024-01
3. The mighty minions of non-small-cell lung cancer: EGFR, ALK, and ROS1;Cancer Research, Statistics, and Treatment;2024-01
4. Testing modalities for ALK-driven lung cancer: A narrative review;Cancer Research, Statistics, and Treatment;2023
5. Amivantamab: Is it really a game changer for EGFR exon 20 insertion mutation?;Cancer Research, Statistics, and Treatment;2023